Advertisement

Current Colorectal Cancer Reports

, Volume 14, Issue 5, pp 152–158 | Cite as

Molecular Variances Between Right- and Left-sided Colon Cancers

  • Alberto Puccini
  • John L. Marshall
  • Mohamed E. SalemEmail author
Personalized Medicine in Colorectal Cancer (D Cunningham and EC Smyth, Section Editors)
  • 135 Downloads
Part of the following topical collections:
  1. Topical Collection on Personalized Medicine in Colorectal Cancer

Abstract

Purpose of Review

During the past few years, several important clinical and molecular differences have been observed simply based on anatomic tumor location of colorectal cancer. With this review, we aimed to give an updated overview of the recent findings on tumor location as a surrogate of embryological, molecular, and clinical differences that have a direct impact on our daily clinical practice.

Recent Findings

Increasing evidence has demonstrated a role for the microbiota in shaping inflammatory environments and promoting CRC growth and spread, and now we know that bacterial phylotypes vary depending on the primary tumor location. Compelling evidence has shown that tumor sidedness has both a strong prognostic and predictive value. In fact, right-sided colon cancers display a markedly worse prognosis compared to left-sided tumors; moreover, it seems that right-sided RAS wild-type metastatic colorectal cancer benefits from bevacizumab-based therapy while left-sided tumors have better outcomes with cetuximab-based treatment in the first-line setting. Since the underlying reasons of these differences are yet unknown, further investigations are warranted in this expanding and relevant field.

Summary

In this review, we summarize the actual knowledge on the clinical, microbiome, and molecular differences observed between right- and left-sided colon cancers. We also present an overview of the existing data on the prognostic and predictive impact of tumor sidedness on metastatic colorectal cancer patient outcome.

Keywords

Left-sided colon cancer Right-sided colon cancer Cetuximab Bevacizumab Microbiota 

Notes

Compliance with Ethics Standards

Conflict of Interest

Alberto Puccini declares that he has no conflict of interest.

John L. Marshall has received compensation from Genentech/Roche, Amgen, Taiho, Caris Life Sciences, Bayer, and Celgene for service as a consultant.

Mohamed E. Salem declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67:177–93.CrossRefPubMedGoogle Scholar
  2. 2.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Yang SY, Cho MS, Kim NK. Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype. Expert Rev Anticancer Ther. 2018;18:351–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Shen H, Yang J, Huang Q, Jiang MJ, Tan YN, Fu JF, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21:6470–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    LaPointe LC, Dunne R, Brown GS, et al. Map of differential transcript expression in the normal human large intestine. Physiol Genomics. 2008;33:50–64.CrossRefPubMedGoogle Scholar
  6. 6.
    Venook A, Niedzwiecki D, Innocenti F, et al. Impact of primary (1°) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2016; 34 (suppl; abstr 3504).CrossRefGoogle Scholar
  7. 7.
    • Loupakis F, Yang D, Yau L et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015; 107. One of the first evidence of the impact of tumor sidedness on CRC patients prognosis.Google Scholar
  8. 8.
    Nitsche U, Stogbauer F, Spath C, et al. Right sided colon cancer as a distinct histopathological subtype with reduced prognosis. Dig Surg. 2016;33:157–63.CrossRefPubMedGoogle Scholar
  9. 9.
    Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, et al. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015;21:5294–304.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Brule SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51:1405–14.CrossRefPubMedGoogle Scholar
  11. 11.
    Arnold D, Lueza B, Douillard JY, Peeters M, Lenz HJ, Venook A, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–29.CrossRefPubMedGoogle Scholar
  12. 12.
    Wong HL, Lee B, Field K, Lomax A, Tacey M, Shapiro J, et al. Impact of primary tumor site on bevacizumab efficacy in metastatic colorectal cancer. Clin Colorectal Cancer. 2016;15:e9–e15.CrossRefPubMedGoogle Scholar
  13. 13.
    Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anti-Cancer Drugs. 2014;25:212–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Tejpar S, Stintzing S, Ciardiello F, Tabernero J, van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncology. 2017;3:194–201.CrossRefGoogle Scholar
  15. 15.
    Wang F, Bai L, Liu TS, Yu YY, He MM, Liu KY, et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34:384–93.PubMedGoogle Scholar
  16. 16.
    Yamauchi M, Morikawa T, Kuchiba A, Imamura Y, Qian ZR, Nishihara R, et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 2012;61:847–54.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Loree JM, Pereira AAL, Lam M, Willauer AN, Raghav K, Dasari A, et al. Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and consensus molecular subtypes. Clin Cancer Res. 2018;24:1062–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Lee GH, Malietzis G, Askari A, Bernardo D, al-Hassi HO, Clark SK. Is right-sided colon cancer different to left-sided colorectal cancer? - a systematic review. Eur J Surg Oncol. 2015;41:300–8.CrossRefPubMedGoogle Scholar
  19. 19.
    Missiaglia E, Jacobs B, D’Ario G, di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25:1995–2001.CrossRefPubMedGoogle Scholar
  20. 20.
    Weiss JM, Pfau PR, O’Connor ES, King J, LoConte N, Kennedy G, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011;29:4401–9.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, et al. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53:57–64.CrossRefPubMedGoogle Scholar
  22. 22.
    Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw. 2017;15:411–9.CrossRefGoogle Scholar
  23. 23.
    Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113:779–88.CrossRefPubMedGoogle Scholar
  24. 24.
    Riihimaki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69–80.CrossRefPubMedGoogle Scholar
  26. 26.
    Brennan CA, Garrett WS. Gut microbiota, inflammation, and colorectal Cancer. Annu Rev Microbiol. 2016;70:395–411.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sears CL, Garrett WS. Microbes, microbiota, and colon cancer. Cell Host Microbe. 2014;15:317–28.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Morgun A, Dzutsev A, Dong X, Greer RL, Sexton DJ, Ravel J, et al. Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut. 2015;64:1732–43.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015;37:223–36.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Sonnenburg ED, Smits SA, Tikhonov M, Higginbottom SK, Wingreen NS, Sonnenburg JL. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016;529:212–5.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Tilg H, Adolph TE, Gerner RR, Moschen AR. The intestinal microbiota in colorectal Cancer. Cancer Cell. 2018;33:954–64.CrossRefPubMedGoogle Scholar
  32. 32.
    Gao Z, Guo B, Gao R, et al. Microbiota disbiosis is associated with colorectal cancer. Front Microbiol. 2015;6:20.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Zhang Y, Hoffmeister M, Weck MN, Chang-Claude J, Brenner H. Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol. 2012;175:441–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Kohoutova D, Smajs D, Moravkova P, Cyrany J, Moravkova M, Forstlova M, et al. Escherichia coli strains of phylogenetic group B2 and D and bacteriocin production are associated with advanced colorectal neoplasia. BMC Infect Dis. 2014;14:733.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Flemer B, Lynch DB, Brown JM, et al. Tumour-associated and non-tumour-associated microbiota in colorectal cancer. Gut. 2017;66:633–43.CrossRefGoogle Scholar
  36. 36.
    Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A. 2014;111:18321–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Sears CL, Pardoll DM. The intestinal microbiome influences checkpoint blockade. Nat Med. 2018;24:254–5.CrossRefPubMedGoogle Scholar
  38. 38.
    • Purcell RV, Visnovska M, Biggs PJ, et al. Distinct gut microbiome patterns associate with consensus molecular subtypes of colorectal cancer. Sci Rep. 2017;7:11590. The authors showed that different bacterial signatures are associated with consensus molecular subtypes (CMS) of CRC.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2017;17:268.CrossRefPubMedGoogle Scholar
  40. 40.
    Puccini A, Berger MD, Naseem M, et al. Colorectal cancer: epigenetic alterations and their clinical implications. Biochim Biophys Acta. 1868;2017:439–48.Google Scholar
  41. 41.
    Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, Issa JPJ. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999;96:8681–6.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Lee MS, McGuffey EJ, Morris JS, et al. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016;114:1352–61.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Seligmann JF, Elliott F, Richman SD et al. Combined Epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab therapy benefit or lack of benefit in patients with RAS wild-type advanced colorectal cancer. JAMA Oncol 2016.Google Scholar
  44. 44.
    Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009;27:5068–74.CrossRefPubMedGoogle Scholar
  45. 45.
    Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17:738–46.CrossRefPubMedGoogle Scholar
  47. 47.
    Salem ME, Weinberg BA, Xiu J, el-Deiry WS, Hwang JJ, Gatalica Z, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8:86356–68.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Puccini A, Berger MD, Zhang W, Lenz HJ. What we know about stage II and III colon cancer: it’s still not enough. Target Oncol. 2017;12:265–75.CrossRefPubMedGoogle Scholar
  50. 50.
    Price TJ, Beeke C, Ullah S, Padbury R, Maddern G, Roder D, et al. Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? Cancer. 2015;121:830–5.CrossRefPubMedGoogle Scholar
  51. 51.
    O’Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, et al. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study. J Clin Oncol. 2001;19:2413–21.CrossRefPubMedGoogle Scholar
  52. 52.
    Peeters M. Outcome according to Left vs. Right side in the panitumumab studies. In. Presented at: ESMO 2016 Congress, Special session. Copenhagen, Denmark. 7–11 October, 2016.Google Scholar
  53. 53.
    Venook A, Niedzwiecki D, Ou F-S et al. Impact of primary tuomor location on Overall Survival and Progression Free Survival in patients with metastatic colorectal cancer: Analysis of all RAS wt subgroup on CALGB/SWOG 80405 (Alliance). Presented at: ESMO 2016 Congress, Special session. Copenhagen, Denmark. 7–11 October, 2016.Google Scholar
  54. 54.
    • Petrelli F, Tomasello G, Borgonovo K et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 2016; DOI:  https://doi.org/10.1001/jamaoncol.2016.4227. Huge meta-analysis that confirms that prognostic value of tumor sidedness in CRC patients.CrossRefGoogle Scholar
  55. 55.
    von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014;140:1607–14.CrossRefGoogle Scholar
  56. 56.
    Boeckx N, Toler A, Op de Beeck K, et al. Primary tumor sidedness impacts on prognosis and treatment outcome: results from three randomized studies of pan- itumumab plus chemotherapy versus chemotherapy or chemo- therapy plus bevacizumab in 1st and 2nd line RAS/BRAF WT mCRC. Ann Oncol. 2016;27(Suppl. 6):vi15e42.Google Scholar
  57. 57.
    Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:87–98.CrossRefPubMedGoogle Scholar
  58. 58.
    Puccini A, Lenz HJ. Colorectal cancer in 2017: practice-changing updates in the adjuvant and metastatic setting. Nat Rev Clin Oncol. 2018;15:77–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Modest DP, Stintzing S, Weikersthal LFv et al. Primary tumor location and efficacy of second-line therapy after initial treatment with FOLFIRI in combination with cetuximab or bevacizumab in patients with metastatic colorectal cancer- FIRE-3 (AIOKRK0306). J Clin Oncol 2017; 35: 3525–3525.CrossRefGoogle Scholar
  60. 60.
    Lenz H-J, Ou F-S, Venook AP et al. Impact of consensus molecular subtyping (CMS) on overall survival (OS) and progression free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 2017; 35 (suppl; abstr 3511).CrossRefGoogle Scholar
  61. 61.
    Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron. 2015;8:15–21.CrossRefPubMedGoogle Scholar
  62. 62.
    Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, et al. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther. 2018;18:251–66.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Alberto Puccini
    • 1
  • John L. Marshall
    • 2
  • Mohamed E. Salem
    • 3
    Email author
  1. 1.Department of Medical OncologyOspedale Policlinico San MartinoGenoaItaly
  2. 2.Ruesch Center for The Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer CenterGeorgetown University Medical CenterWashingtonUSA
  3. 3.Department of Medical Oncology, Levine Cancer InstituteCarolinas HealthCare SystemCharlotteUSA

Personalised recommendations